District Court of New York Dismisses FTC Complaint against Quincy Bioscience
MADISON, Wis. (Oct. 2, 2017) — On September 29, Judge Louis Stanton of the U.S. District Court in the Southern District of New York dismissed the Federal Trade Commission and the New York Attorney General’s complaint against Quincy Bioscience, the makers of Prevagen. John Villafranco, partner at Kelley Drye and counsel representing Quincy Bioscience in the complaint, released the following statement:
“We are very pleased with the Judge’s decision today,” said John Villafranco. “We continue to believe that Quincy Bioscience has presented substantial evidence in support of its claims about Prevagen.”
About Quincy Bioscience
Quincy Bioscience is a biotechnology company based in Madison, Wisconsin, focused on the discovery, development and commercialization of novel technologies to support brain health, with a specific emphasis on memory support and cognitive health. Quincy Bioscience is set apart by its cutting-edge applications of the patented protein apoaequorin, which has been tested to show improvements in cognition and memory in clinical trials.